Evidence map›Paper›PMID 37886524›Full record

ArticleResearch square2023

GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults.

Lara Cheslow, Matthew Byrne, Jessica S Kopenhaver, Lorraine Iacovitti, Richard J Smeyne, Adam E Snook, Scott A Waldman

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lara CheslowDepartment of Pharmacology, Physiology, & Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.ORCID 0000-0003-0880-5957
Matthew ByrneDepartment of Neurosciences, Thomas Jefferson University, Philadelphia, PA, USA.
Jessica S KopenhaverDepartment of Pharmacology, Physiology, & Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
Lorraine IacovittiDepartment of Neurosciences, Thomas Jefferson University, Philadelphia, PA, USA.
Richard J SmeyneDepartment of Neurosciences, Thomas Jefferson University, Philadelphia, PA, USA.ORCID 0000-0002-8459-5472
Adam E SnookDepartment of Pharmacology, Physiology, & Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.ORCID 0000-0001-9216-4560
Scott A WaldmanDepartment of Pharmacology, Physiology, & Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
Thomas Jefferson University · US

Funding

Using reporter human iPS cells to study fate, function and Parkinson's diseaseR01NS075839 · NINDS · THOMAS JEFFERSON UNIVERSITY · PI IACOVITTI, LORRAINE · 2012 to 2021
$3.8M
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformationR01CA206026 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A · 2016 to 2020
$1.8M
Neuroprotection by the GUCY2C gut-brain axis in Parkinson's diseaseR21NS130388 · NINDS · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A · 2023 to 2023
$429k
Off-the-shelf CAR-T Therapy via Tumor-Selective Immuno-engagersR21CA267087 · NCI · LEHIGH UNIVERSITY · PI SNOOK, ADAM, THEVENIN, DAMIEN · 2022 to 2023
$402k
Parkinson's disease therapies targeting GUCY2CF30NS125921 · NINDS · THOMAS JEFFERSON UNIVERSITY · PI CHESLOW, LARA · 2022 to 2025
$179k
NCI NIH HHS R01 CA206026NCI NIH HHS R21 CA267087NINDS NIH HHS F30 NS125921NINDS NIH HHS R01 NS075839NINDS NIH HHS R21 NS130388
6 · The paper itself

Abstract

Mitochondrial dysfunction and reactive oxygen species (ROS) accumulation within the substantia nigra pars compacta (SNpc) are central drivers of dopaminergic (DA) neuron death in Parkinson's disease (PD). Guanylyl cyclases, and their second messengers cyclic (c)GMP, support mitochondrial function, protecting against ROS and promoting cell survival in a number of tissues. However, the role of the guanylyl cyclase-cGMP axis in defining the vulnerability of DA neurons in the SNpc in PD remains unclear, in part due to the challenge of manipulating cGMP levels selectively in midbrain DA neurons. In that context, guanylyl cyclase C (GUCY2C), a receptor primarily expressed by intestinal epithelial cells, was discovered recently in midbrain DA neurons. Here, we demonstrate that GUCY2C promotes mitochondrial function, reducing oxidative stress and protecting DA neurons from degeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of neurodegeneration. GUCY2C is overexpressed in the SNpc in PD patients and in mice treated with MPTP, possibly reflecting a protective response to oxidative stress. Moreover, cGMP signaling protects against oxidative stress, mitochondrial impairment, and cell death in cultured DA neurons. These observations reveal a previously unexpected role for the GUCY2C-cGMP signaling axis in controlling mitochondrial dysfunction and toxicity in nigral DA neurons, highlighting the therapeutic potential of targeting DA neuron GUCY2C to prevent neurodegeneration in PD.

Indexed as

cyclic GMPdopaminergic neuronsGUCY2CmitochondriaMPTPParkinson’s diseaseROS

Identifiers

PMID37886524
PMCPMC10602097
OpenAlexW4387582394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.